The Filings Report

United Therapeutics Corp

UTHRNasdaqCIK 1082554Healthcare / Drug Manufacturersfiscal year ends December69 quarters since 2009

Revenue, Q2 FY2026
$783M
−1.9% on Q2 FY2025
Net income
$333M
+7.6% on Q2 FY2025
Free cash flow
$206M
+58.8% on Q2 FY2025
Diluted EPS
$7.27
+13.4% on Q2 FY2025
Revenue, TTM
$3.2B
trailing four quarters
Net margin, TTM
41.6%
net income $1.3B
Free cash flow, TTM
$1.1B
$1.7B less $592M capex
Cash and equivalents
$1.8B
long-term debt —, Jun 30, 2026
Shares, 12-month change
−5.2%
43M shares, Jun 30, 2026
Buybacks, TTM
$2.5B
9.7% of market value
Dividends, TTM
—
no yield
Market value
$25.7B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, United Therapeutics Corp reported revenue of $783M, −1.9% on Q2 FY2025, and net income of $333M (+7.6%). Operating margin was 42.2%. Free cash flow, operating cash flow less capital expenditures, was $206M ($314M less $108M). Diluted earnings per share were $7.27.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
$0$200M$400M$600M$800MQ3'22, Revenue: $516MQ3'22, Net income: $239MQ3'22Q4'22, Revenue: $492MQ4'22, Net income: $132MQ4'22Q1'23, Revenue: $507MQ1'23, Net income: $241MQ1'23Q2'23, Revenue: $597MQ2'23, Net income: $259MQ2'23Q3'23, Revenue: $609MQ3'23, Net income: $268MQ3'23Q4'23, Revenue: $615MQ4'23, Net income: $217MQ4'23Q1'24, Revenue: $678MQ1'24, Net income: $307MQ1'24Q2'24, Revenue: $715MQ2'24, Net income: $278MQ2'24Q3'24, Revenue: $749MQ3'24, Net income: $309MQ3'24Q4'24, Revenue: $736MQ4'24, Net income: $301MQ4'24Q1'25, Revenue: $794MQ1'25, Net income: $322MQ1'25Q2'25, Revenue: $799MQ2'25, Net income: $310MQ2'25Q3'25, Revenue: $800MQ3'25, Net income: $339MQ3'25Q4'25, Revenue: $790MQ4'25, Net income: $364MQ4'25Q1'26, Revenue: $782MQ1'26, Net income: $275MQ1'26Q2'26, Revenue: $783MQ2'26, Net income: $333MQ2'26$0$200M$400M$600M$800MQ3'22, Revenue: $516MQ3'22, Net income: $239MQ4'22, Revenue: $492MQ4'22, Net income: $132MQ4'22Q1'23, Revenue: $507MQ1'23, Net income: $241MQ2'23, Revenue: $597MQ2'23, Net income: $259MQ2'23Q3'23, Revenue: $609MQ3'23, Net income: $268MQ4'23, Revenue: $615MQ4'23, Net income: $217MQ4'23Q1'24, Revenue: $678MQ1'24, Net income: $307MQ2'24, Revenue: $715MQ2'24, Net income: $278MQ2'24Q3'24, Revenue: $749MQ3'24, Net income: $309MQ4'24, Revenue: $736MQ4'24, Net income: $301MQ4'24Q1'25, Revenue: $794MQ1'25, Net income: $322MQ2'25, Revenue: $799MQ2'25, Net income: $310MQ2'25Q3'25, Revenue: $800MQ3'25, Net income: $339MQ4'25, Revenue: $790MQ4'25, Net income: $364MQ4'25Q1'26, Revenue: $782MQ1'26, Net income: $275MQ2'26, Revenue: $783MQ2'26, Net income: $333MQ2'26

Net income losses drawn in red.

Free cash flow
$0$100M$200M$300M$400MQ3'22, Free cash flow: $190MQ3'22Q4'22, Free cash flow: $89MQ4'22Q1'23, Free cash flow: $334MQ1'23Q2'23, Free cash flow: $62MQ2'23Q3'23, Free cash flow: $281MQ3'23Q4'23, Free cash flow: $72MQ4'23Q1'24, Free cash flow: $338MQ1'24Q2'24, Free cash flow: $187MQ2'24Q3'24, Free cash flow: $301MQ3'24Q4'24, Free cash flow: $255MQ4'24Q1'25, Free cash flow: $386MQ1'25Q2'25, Free cash flow: $130MQ2'25Q3'25, Free cash flow: $352MQ3'25Q4'25, Free cash flow: $173MQ4'25Q1'26, Free cash flow: $363MQ1'26Q2'26, Free cash flow: $206MQ2'26$0$100M$200M$300M$400MQ3'22, Free cash flow: $190MQ4'22, Free cash flow: $89MQ4'22Q1'23, Free cash flow: $334MQ2'23, Free cash flow: $62MQ2'23Q3'23, Free cash flow: $281MQ4'23, Free cash flow: $72MQ4'23Q1'24, Free cash flow: $338MQ2'24, Free cash flow: $187MQ2'24Q3'24, Free cash flow: $301MQ4'24, Free cash flow: $255MQ4'24Q1'25, Free cash flow: $386MQ2'25, Free cash flow: $130MQ2'25Q3'25, Free cash flow: $352MQ4'25, Free cash flow: $173MQ4'25Q1'26, Free cash flow: $363MQ2'26, Free cash flow: $206MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$500M$1.0B$1.5B$2.0BQ3'22, Cash and equivalents: $967MQ3'22Q4'22, Cash and equivalents: $961MQ4'22Q1'23, Cash and equivalents: $1.2BQ1'23Q2'23, Cash and equivalents: $1.1BQ2'23Q3'23, Cash and equivalents: $1.1BQ3'23Q4'23, Cash and equivalents: $1.2BQ4'23Q1'24, Cash and equivalents: $1.3BQ1'24Q2'24, Cash and equivalents: $1.4BQ2'24Q3'24, Cash and equivalents: $1.6BQ3'24Q4'24, Cash and equivalents: $1.7BQ4'24Q1'25, Cash and equivalents: $1.9BQ1'25Q2'25, Cash and equivalents: $1.6BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25Q4'25, Cash and equivalents: $1.6BQ4'25Q1'26, Cash and equivalents: $1.3BQ1'26Q2'26, Cash and equivalents: $1.8BQ2'26$0$500M$1.0B$1.5B$2.0BQ3'22, Cash and equivalents: $967MQ4'22, Cash and equivalents: $961MQ4'22Q1'23, Cash and equivalents: $1.2BQ2'23, Cash and equivalents: $1.1BQ2'23Q3'23, Cash and equivalents: $1.1BQ4'23, Cash and equivalents: $1.2BQ4'23Q1'24, Cash and equivalents: $1.3BQ2'24, Cash and equivalents: $1.4BQ2'24Q3'24, Cash and equivalents: $1.6BQ4'24, Cash and equivalents: $1.7BQ4'24Q1'25, Cash and equivalents: $1.9BQ2'25, Cash and equivalents: $1.6BQ2'25Q3'25, Cash and equivalents: $1.3BQ4'25, Cash and equivalents: $1.6BQ4'25Q1'26, Cash and equivalents: $1.3BQ2'26, Cash and equivalents: $1.8BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

United Therapeutics Corp income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue783782790800799794736749−1.9%
Cost of revenue10013310310188937683+13.6%
Gross profit684648687699711702660666−3.8%
Research and development146138140128134149134104+9.2%
Selling, general and administrative207184191183213170169219−2.7%
Operating income331326357389365383358343−9.2%
Other income (expense)42(7)875044413946−4.6%
Pretax income373318444438408424397389−8.7%
Income tax40438099991019580−59.9%
Net income333275364339310322301309+7.6%
Diluted EPS ($)7.275.82—7.166.416.63—6.39+13.4%
Diluted shares (millions)4647—474849—48—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

United Therapeutics Corp balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents1,8031,2801,5571,3401,5931,9001,6971,554+13.2%
Short-term investments8598741,3631,4281,4561,4211,5701,773−41.0%
Total current assets3,4842,8723,7033,4943,8273,9403,8744,000−9.0%
Total assets7,2206,7147,8807,3517,9087,7447,3647,123−8.7%
Total current liabilities608599561546527722738873+15.3%
Long-term debt—————————
Total liabilities8208137847617349379201,022+11.6%
Stockholders’ equity6,4005,9017,0966,5907,1746,8076,4446,101−10.8%
Shares outstanding (millions)4342444345454545—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

United Therapeutics Corp cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 25, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed Apr 30, 2025Q4 FY2024ended Dec 31, 2024filed Feb 26, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow314463346562192461341377+63.6%
Capital expenditures10810117321162758777+73.6%
Free cash flow (CFO − capex)206363173352130386255301+58.8%
Depreciation and amortization2423232221202019+14.7%
Share repurchases01,50001,0000000—
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 25, 2026.

Income statement

United Therapeutics Corp income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Revenue3,1832,8772,3281,9361,6861,4831,4491,6281,7251,5991,4661,2891,117916743593359281
Cost of revenue38431025815212310811819910673————————
Gross profit2,7982,5682,0701,7851,5631,3751,331————1,154976787652524317—
Research and development5504814083235403581,183358265148245243299173180165120239
Selling, general and administrative756710477482467——26633031745338139420215618917294
Operating income1,4931,3771,185980556594(188)8058151,06269953929242231817126(82)
Other income (expense)22116289(29)384523(46)(45)(1)345(14)(14)19(19)(16)(7)(2)
Pretax income1,7141,5391,274951594639(165)7597701,0601,04452527944129915519—
Income tax379344290223118124(60)1703523473931851041368244(1)(34)
Net income1,3351,195985727476—————————————
Diluted EPS ($)27.8624.6419.8115.0010.0611.54(2.39)13.399.3115.2512.726.283.285.713.671.780.35(1.08)
Diluted shares (millions)484950494745444445475154535359605646

Balance sheet

United Therapeutics Corp balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Cash and equivalents1,5571,6971,2089618957397386697051,023832398284159168252100129
Short-term investments1,3631,5701,7861,8781,0361,09674874722228————————
Total current assets3,7033,8743,5513,3802,3242,1671,8651,7681,4481,4251,275958914668562764325—
Total assets7,8807,3647,1676,0455,1694,6153,9133,4012,8792,3262,1841,8842,0881,6271,5181,4321,052—
Total current liabilities561738804343305323463277445333441504688177213429330—
Long-term debt——————————————————
Total liabilities7849201,1821,2481,2101,2201,133593758463585619783532559537388—
Stockholders’ equity7,0966,4445,9854,7973,9593,3952,7802,7892,1021,8511,5891,2431,2591,084948884653555
Shares outstanding (millions)44454746454544444345454750505458——

Cash flow statement

United Therapeutics Corp cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 25, 2026FY2024ended Dec 31, 2024filed Feb 26, 2025FY2023ended Dec 31, 2023filed Feb 21, 2024FY2022ended Dec 31, 2022filed Feb 22, 2023FY2021ended Dec 31, 2021filed Feb 24, 2022FY2020ended Dec 31, 2020filed Feb 24, 2021FY2019ended Dec 31, 2019filed Feb 26, 2020FY2018ended Dec 31, 2018filed Feb 27, 2019FY2017ended Dec 31, 2017filed Feb 21, 2018FY2016ended Dec 31, 2016filed Feb 22, 2017FY2015ended Dec 31, 2015filed Feb 25, 2016FY2014ended Dec 31, 2014filed Feb 24, 2015FY2013ended Dec 31, 2013filed Feb 25, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 28, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Jul 28, 2010FY2008ended Dec 31, 2008filed Jul 28, 2010
Operating cash flow1,5611,327978803598756(207)778474644383——324250212100(40)
Capital expenditures52124723013912159841848638504732112361995124
Free cash flow (CFO − capex)1,0411,081748664477696(290)594388606333——2122141934(165)
Depreciation and amortization86735351505046363132333231272118115
Share repurchases1,0001,00000————25050039548342188212———
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$340M
818 sales by 3 insiders; officers and directors $340M
Bought, twelve months
$864K
1 purchases by 1 insider; officers and directors $864K
Sold, twelve months
$1.5B
2842 sales by 12 insiders; officers and directors $1.5B

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoroption exerciseindirect9,500$117.76$1M333,943Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect53$590.43$31K333,890Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,104$591.90$653K332,786Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,563$592.97$927K331,223Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,540$593.88$915K329,683Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,248$594.89$742K328,435Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,678$595.88$1000K326,757Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,355$596.86$809K325,402Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect919$597.66$549K324,483Oct 30, 2026
Oct 29, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect40$599.30$24K324,443Oct 30, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoroption exerciseindirect9,500$117.76$1M333,943Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect821$583.50$479K333,122Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect2,625$584.43$2M330,497Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,902$585.36$1M328,595Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect3,086$586.37$2M325,509Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect986$587.27$579K324,523Oct 29, 2026
Oct 28, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect80$588.39$47K324,443Oct 29, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoroption exerciseindirect9,500$117.76$1M333,943Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect89$582.66$52K333,854Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect807$583.94$471K333,047Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,417$584.83$829K331,630Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect470$585.72$275K331,160Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,417$586.93$832K329,743Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,320$587.88$776K328,423Oct 28, 2026
Oct 27, 2026Rothblatt Martine AChairperson & CEO, Directoropen-market sale10b5-1indirect1,597$588.95$941K326,826Oct 28, 2026

Full insider history for United Therapeutics Corp, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
United Therapeutics Corporation, CIK 1082554 on EDGAR
Extract generated
November 1, 2026
Withheld
none
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense, OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: not filed
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/UTHR.json